Contrast-Enhanced Ultrasound vs Conventional US-guided Percutaneous Needle Biopsy for Pancreatic Diseases: Prospective Multicenter Randomized Controlled Trial

According to previous studies, contrast-enhanced ultrasound (CEUS) -guided Core Biopsy(GB) could improve the diagnosis of biopsy in liver and other superficial mass compared to conventional US-GB. The purpose of this randomized trial is to estimate whether CEUS-GB achieve excellent diagnostic value to conventional US-GB in percutaneous biopsy for pancreatic diseases.

Inclusion Criteria:Age ≥18 years, WHO/ECOG scores <2;Radiographic examination reveal focal pancreatic lesions;No history of local treatment for pancreatic lesions, systemic chemotherapy, targeting, immunotherapy, etc;Normal organ function, including the following criteria:Routine blood test: Hb≥80 g/L; PLT≥50×109/L;Coagulation function test: PT<20s.Exclusion Criteria:The lesions could not be shown by ultrasound and contrast-enhanced ultrasound;Allergic to ultrasound contrast agent;Cardiovascular and cerebrovascular diseases, liver, kidney and lung failure with significant clinical symptoms;History of unexplained bleeding, severe anemia, bleeding tendency or uncorrected coagulopathy;Combined with active infection;Massive ascites;Patients or family members do not agree to enter the study;Pregnant or lactating women;The investigator considers that there are any other factors that may be inappropriate for inclusion or affect the subject's participation in the study.